Breast Cancer Clinical Trial
— ALIENOROfficial title:
Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study)
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | October 2024 |
Est. primary completion date | October 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria : 1. Age = 18 years (no age limit). 2. Women or men. 3. Invasive breast cancer proven histologically at diagnosis (before neoadjuvant chemotherapy): 1. Locally advanced tumor known to be inoperable from the start: - cT4a, b, c, d whatever the cN - or cN2 or cN3 whatever the cT. 2. Operable tumors: - cT2cN1 or cT3cN0 or cT3N1, - or cT2cN0 for which ganglionic invasion has been proven by cytology or histology. 4. Lack of clinically or radiologically detectable metastases in the initial diagnosis before the neoadjuvant chemotherapy (M0). 5. Unilateral or bilateral breast cancer. Multifocality is accepted. 6. Patients who received 6 to 8 cycles of neoadjuvant chemotherapy. 7. Preoperative radiation therapy allowed. 8. Breast surgery performed and pathology report of a non-complete histological response (i.e. all the different results of ypT0 /is ypN0). 9. Signed informed consent. 10. Patients affiliated to a French social security scheme in accordance with Article 1121-11 of the French Code of Public Health. 11. Possible inclusion in another interventional research (surgical, radiotherapy or drug study). Exclusion Criteria : 1. cT2cN0 tumor without cytological or histological lymph node involvement. 2. Progression during neoadjuvant chemotherapy. 3. Exclusive neoadjuvant hormone therapy. 4. Complete blood transfusion within 120 days prior to 1st sampling. 5. History of invasive cancer regardless of the time elapsed since the diagnosis of this cancer, including a history of contralateral invasive breast cancer. However, patients who have been treated for in situ breast cancer, basocellular skin cancer or cervical cancer treated in situ are eligible. 6. Patient unable to follow and comply with research procedures for geographical, social or psychological reasons. 7. Patient deprived of liberty or subject to a legal protection measure. |
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonie | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Institut Bergonié | Fondation Bergonié |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prognostic value of the presence of ctDNA mutation(s) measured by dPCR on recurrence-free interval (RFI) at 3 years. | 3 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on overall survival (OS) at 3 years. | 3 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on distant-metastasis-free interval (DRFI) at 3 years. | 3 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on OS at 5 years. | 5 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on DRFI at 5 years. | 5 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on a single sample assessment after surgery (measured by dPCR) on RFI at 3 years. | 3 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on a single sample assessment after surgery (measured by dPCR) on DRFI at 3 years. | 3 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on a single sample assessment after surgery (measured by dPCR) on RFI at 5 years. | 5 years | ||
Secondary | Prognostic value of the presence of ctDNA mutation(s) on a single sample assessment after surgery (measured by dPCR) on DRFIat 5 years. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |